This program focuses on frontline therapies for patients with metastatic melanoma. It discusses strategies for sequencing immune checkpoint inhibitors (ICIs) and patient characteristics that guide choice of treatment. The program includes topics such as the scientific rationale driving research, efficacy and safety data from recent pivotal clinical trials, and clinical management dilemmas. This program provides busy clinicians with an opportunity to listen to experts discuss critical takeaways from research studies and implications for current practice, such as treatment selection and effective management of treatment-related adverse events (AEs). Learners will be able to better understand optimal treatment sequencing while becoming more aware of clinical challenges associated with immunotherapy, such as toxicity management as well as difficult patient scenarios.

This program focuses on frontline therapies for patients with metastatic melanoma. It discusses strategies for sequencing immune checkpoint inhibitors (ICIs) and patient characteristics that guide choice of treatment. The program includes topics such as the scientific rationale driving research, efficacy and safety data from recent pivotal clinical trials, and clinical management dilemmas. This program provides busy clinicians with an opportunity to listen to experts discuss critical takeaways from research studies and implications for current practice, such as treatment selection and effective management of treatment-related adverse events (AEs). Learners will be able to better understand optimal treatment sequencing while becoming more aware of clinical challenges associated with immunotherapy, such as toxicity management as well as difficult patient scenarios.

In this short medical minute, Bruce E. Sands, MD, MS, an expert in IBD management, discusses the latest in treat-to-target and therapeutic drug monitoring in patients with IBD.

In this brief medical minute, Bruce E. Sands, MD, MS, an expert in IBD discusses the clinical challenges of IBD management including biologic failure and surgical management.

In this brief medical minute, two experts in IBD, Abigail Meyers, PA-C and Bruce E. Sands, MD, MS, discuss collaborative and holistic care for IBD management.

This Medical Minute will discuss how to identify and target objective measures of ulcerative colitis disease activity to achieve mucosal healing.

An expert in IBD discusses the latest in early diagnosis, individualizing therapy, and monitoring of IBD. Hear about early signs and symptoms of IBD as well as strategies for individualizing initial therapy in patients with IBD based on available agents and guidelines.

In this brief medical minute, Abigail Meyers, PA-C, an expert in IBD, discusses strategies to address the clinical challenges of IBD management during pregnancy and engaging patients in shared decision-making.

The 5-year recurrence rates for stage IIB and IIC melanoma are up to 46%, but now new immunotherapy options are FDA-approved for the adjuvant treatment of stage IIB and IIC melanoma. Find out why this matters and hear Drs. Jason Luke and Tara Mitchell break down the latest data on treating stage IIB and IIC melanoma with adjuvant immunotherapy.

Vision loss due to diabetes is preventable, yet minority patients and patients of low socioeconomic status remain at a disproportionate risk of poor outcomes. Find out what Dr. Pradeep Prasad and Dr. Charles Vega are doing to curb the negative outcomes of diabetic eye disease in their patients at high risk for vision loss.